Atara Biotherapeutics, Inc.
ATRA· Nasdaq
Released Nov 12, 2024, after the close
10-Q filed Nov 12, 2024, 43 days after period end · 0000950170-24-125389
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $40.19M | $2.14M | $4.46M | — |
| Net Income | -$21.91M | -$69.80M | -$84.09M | -$84.66M |
| EPS Diluted |
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
| -$2.93 |
| -$16.40 |
| -$0.82 |
| -$0.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.